ketanserin has been researched along with Hypertension, Pulmonary in 27 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective randomized trial in patients with a history of preoperative pulmonary hypertension who were undergoing surgery for valvular replacement or annuloplasty, the effects of ketanserin (KET) (12 patients) and sodium nitroprusside (SNP) (14 patients) on the systemic and pulmonary circulation and pulmonary shunt fraction (Qsp/Qt) were studied in the immediate postoperative period." | 9.06 | Ketanserin in the treatment of pulmonary hypertension after valvular surgery: a comparison with sodium nitroprusside. ( Feld, RJ; Reneman, RS; van der Starre, PJ, 1989) |
| "There has been suggestion of a possible relationship between the intake of the appetite suppressant dexfenfluramine and the development of primary pulmonary hypertension." | 7.69 | Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. ( Delcroix, M; Leeman, M; Maggiorini, M; Naeije, R; Wauthy, P, 1995) |
| "To indirectly test the hypothesis whether serotonin (5-HT) might have a role in the increase in pulmonary vascular resistance, we evaluated the haemodynamic and gas exchange response of intravenous ketanserin (K), a 5-HT receptor inhibitor, in eight severe but stable patients with chronic obstructive pulmonary disease with secondary pulmonary hypertension (mean pulmonary artery pressure (Ppa) 30." | 7.69 | Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. ( Domenighetti, G; Feihl, F; Leuenberger, P, 1997) |
| "The acute hemodynamic effect of intravenous ketanserin, an S2-serotonergic receptor antagonist, was evaluated during right heart catheterization in 20 patients with primary pulmonary hypertension." | 7.67 | Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. ( McGoon, MD; Vlietstra, RE, 1987) |
| "A selective antagonist of S2-serotonergic receptors, ketanserin, was administered intravenously during right heart catheterization to 14 patients with pulmonary hypertension complicating systemic sclerosis." | 7.67 | Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. ( Kostis, JB; Molony, RR; Ruddy, MC; Seibold, JR; Turkevich, D, 1987) |
| "In a prospective randomized trial in patients with a history of preoperative pulmonary hypertension who were undergoing surgery for valvular replacement or annuloplasty, the effects of ketanserin (KET) (12 patients) and sodium nitroprusside (SNP) (14 patients) on the systemic and pulmonary circulation and pulmonary shunt fraction (Qsp/Qt) were studied in the immediate postoperative period." | 5.06 | Ketanserin in the treatment of pulmonary hypertension after valvular surgery: a comparison with sodium nitroprusside. ( Feld, RJ; Reneman, RS; van der Starre, PJ, 1989) |
| " During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)." | 3.72 | Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003) |
| "There has been suggestion of a possible relationship between the intake of the appetite suppressant dexfenfluramine and the development of primary pulmonary hypertension." | 3.69 | Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. ( Delcroix, M; Leeman, M; Maggiorini, M; Naeije, R; Wauthy, P, 1995) |
| "To indirectly test the hypothesis whether serotonin (5-HT) might have a role in the increase in pulmonary vascular resistance, we evaluated the haemodynamic and gas exchange response of intravenous ketanserin (K), a 5-HT receptor inhibitor, in eight severe but stable patients with chronic obstructive pulmonary disease with secondary pulmonary hypertension (mean pulmonary artery pressure (Ppa) 30." | 3.69 | Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. ( Domenighetti, G; Feihl, F; Leuenberger, P, 1997) |
| "Serotonin can induce pulmonary hypertension, hypoxia and bronchoconstriction, and ketanserin has been shown to reverse these effects on various experimental models of acute respiratory failure." | 3.67 | Effects of serotonin inhibition in air embolism in dogs. ( Domb, M; Goldstein, J; Lignan, H; Vincent, JL, 1988) |
| "The acute hemodynamic effect of intravenous ketanserin, an S2-serotonergic receptor antagonist, was evaluated during right heart catheterization in 20 patients with primary pulmonary hypertension." | 3.67 | Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension. ( McGoon, MD; Vlietstra, RE, 1987) |
| "A selective antagonist of S2-serotonergic receptors, ketanserin, was administered intravenously during right heart catheterization to 14 patients with pulmonary hypertension complicating systemic sclerosis." | 3.67 | Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. ( Kostis, JB; Molony, RR; Ruddy, MC; Seibold, JR; Turkevich, D, 1987) |
| "Methiothepin did not inhibit pulmonary vascular contractility per se, because the pulmonary hypertensive response to the thromboxane A2 mimetic U44069 remained intact in methiothepin-treated broilers." | 2.72 | Evaluation of the serotonin receptor blockers ketanserin and methiothepin on the pulmonary hypertensive responses of broilers to intravenously infused serotonin. ( Chapman, ME; Wideman, RF, 2006) |
| "Primary pulmonary hypertension is an uncommon but serious disease that often results in debilitating symptoms and early death." | 2.37 | Vasodilator therapy for primary pulmonary hypertension. ( McGoon, MD; Vlietstra, RE, 1984) |
| "Treatment with ketanserin attenuated bleomycin-induced PH (increased RVSP and RVH) and pulmonary vascular remodeling (decreased vessel density and increased muscularization of small vessels)." | 1.48 | Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice. ( Delaney, C; Fisher, S; Maltzahn, J; Nozik-Grayck, E; Sherlock, L; Wright, C, 2018) |
| "Pretreatment with fasudil, a Rho kinase inhibitor, blunted the effects of 5-HT infusion." | 1.37 | Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. ( Abman, SH; Delaney, C; Gien, J; Grover, TR; Roe, G, 2011) |
| "Ketanserin was used as 5-HT2-serotonergic antagonist." | 1.27 | Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin. ( Arnold, G; Breuer, HW; Breuer, J; Meschig, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (40.74) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 5 (18.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delaney, C | 3 |
| Sherlock, L | 1 |
| Fisher, S | 1 |
| Maltzahn, J | 1 |
| Wright, C | 1 |
| Nozik-Grayck, E | 1 |
| Gien, J | 2 |
| Roe, G | 2 |
| Isenberg, N | 1 |
| Kailey, J | 1 |
| Abman, SH | 2 |
| Chen, C | 1 |
| Han, X | 1 |
| Fan, F | 2 |
| Liu, Y | 2 |
| Wang, T | 1 |
| Wang, J | 1 |
| Hu, P | 1 |
| Ma, A | 1 |
| Tian, H | 2 |
| Grover, TR | 1 |
| Yan, X | 1 |
| Wang, W | 1 |
| Han, J | 1 |
| Marcos, E | 1 |
| Adnot, S | 1 |
| Pham, MH | 1 |
| Nosjean, A | 1 |
| Raffestin, B | 1 |
| Hamon, M | 1 |
| Eddahibi, S | 1 |
| Deuchar, GA | 1 |
| Hicks, MN | 1 |
| MacLean, MR | 2 |
| Chapman, ME | 1 |
| Wideman, RF | 1 |
| McGoon, MD | 2 |
| Vlietstra, RE | 2 |
| Hechtman, HB | 2 |
| Valeri, CR | 2 |
| Shepro, D | 2 |
| Meuleman, TR | 1 |
| Hill, DC | 1 |
| Port, JD | 1 |
| Stanley, TH | 1 |
| Pace, NL | 1 |
| Mohammad, SF | 1 |
| Naeije, R | 1 |
| Wauthy, P | 1 |
| Maggiorini, M | 1 |
| Leeman, M | 1 |
| Delcroix, M | 1 |
| Quero Jiménez, MC | 1 |
| Burgueros Valero, M | 1 |
| González Dieguez, C | 1 |
| Domínguez Pérez, F | 1 |
| Pinto Corraliza, J | 1 |
| Rodríguez Fernández, M | 1 |
| Sweeney, G | 1 |
| Baird, M | 1 |
| McCulloch, KM | 1 |
| Houslay, M | 1 |
| Morecroft, I | 1 |
| van der Starre, PJ | 2 |
| Solinas, C | 1 |
| Domenighetti, G | 1 |
| Leuenberger, P | 1 |
| Feihl, F | 1 |
| Egermayer, P | 1 |
| Town, GI | 1 |
| Peacock, AJ | 1 |
| Dehring, DJ | 1 |
| Herve, P | 1 |
| Drouet, L | 1 |
| Dosquet, C | 1 |
| Launay, JM | 1 |
| Rain, B | 1 |
| Simonneau, G | 1 |
| Caen, J | 1 |
| Duroux, P | 1 |
| Breuer, J | 1 |
| Meschig, R | 1 |
| Breuer, HW | 1 |
| Arnold, G | 1 |
| Feld, RJ | 1 |
| Reneman, RS | 1 |
| Demling, RH | 1 |
| Wong, C | 1 |
| Fox, R | 1 |
| Hechtman, H | 1 |
| Huval, W | 1 |
| Hamet, A | 1 |
| Král, B | 1 |
| Cernohorský, D | 1 |
| Huval, WV | 1 |
| Lelcuk, S | 1 |
| Feingold, H | 1 |
| Vincent, JL | 1 |
| Goldstein, J | 1 |
| Domb, M | 1 |
| Lignan, H | 1 |
| Seibold, JR | 1 |
| Molony, RR | 1 |
| Turkevich, D | 1 |
| Ruddy, MC | 1 |
| Kostis, JB | 1 |
4 reviews available for ketanserin and Hypertension, Pulmonary
| Article | Year |
|---|---|
Vasodilator therapy for primary pulmonary hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Blood Pressure; Calcium Channel Blockers; Ca | 1984 |
Role of humoral mediators in adult respiratory distress syndrome.
Topics: Animals; Arachidonic Acids; Chemotaxis, Leukocyte; Chromones; Dogs; Guinea Pigs; Humans; Hypertensio | 1984 |
[Management of pulmonary circulation alterations].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Ca | 1993 |
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.
Topics: Blood Platelet Disorders; Collagen Diseases; Humans; Hypertension, Portal; Hypertension, Pulmonary; | 1999 |
2 trials available for ketanserin and Hypertension, Pulmonary
| Article | Year |
|---|---|
Evaluation of the serotonin receptor blockers ketanserin and methiothepin on the pulmonary hypertensive responses of broilers to intravenously infused serotonin.
Topics: Animals; Blood Pressure; Chickens; Hypertension, Pulmonary; Injections, Intravenous; Ketanserin; Mal | 2006 |
Ketanserin in the treatment of pulmonary hypertension after valvular surgery: a comparison with sodium nitroprusside.
Topics: Drug Evaluation; Ferricyanides; Heart Valves; Hemodynamics; Humans; Hypertension, Pulmonary; Ketanse | 1989 |
21 other studies available for ketanserin and Hypertension, Pulmonary
| Article | Year |
|---|---|
Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Bleomycin; Bronchopulmonary Dysplasia; Hyper | 2018 |
Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn.
Topics: Adult; Animals; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Familial Primary Pulmona | 2013 |
Serotonin drives the activation of pulmonary artery adventitial fibroblasts and TGF-β1/Smad3-mediated fibrotic responses through 5-HT(2A) receptors.
Topics: Adventitia; Animals; Cell Proliferation; Connective Tissue Growth Factor; Extracellular Matrix; Fibr | 2014 |
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dose-Response Relationship, Drug; Female; Fe | 2011 |
Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Familial Primary Pu | 2013 |
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal | 2003 |
The role of 5-hydroxytryptamine in the control of pulmonary vascular tone in a rabbit model of pulmonary hypertension secondary to left ventricular dysfunction.
Topics: Animals; Aorta; Blood Pressure; Cardiac Output; Disease Models, Animal; Heart Rate; Hypertension, Pu | 2005 |
Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
Topics: Animals; Dogs; Epinephrine; Hemodynamics; Hypertension, Pulmonary; Ketanserin; Male; Oxygen; Piperid | 1983 |
Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs.
Topics: Animals; Dogs; Fenfluramine; Hypertension, Pulmonary; Hypoxia; Ketanserin; Pulmonary Artery; Pulmona | 1995 |
5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.
Topics: Animals; Cyclic AMP; Cyclic GMP; Hypertension, Pulmonary; In Vitro Techniques; Ketanserin; Male; Pot | 1996 |
Ketanserin in the treatment of protamine-induced pulmonary hypertension.
Topics: Aged; Coronary Artery Bypass; Heart Valve Prosthesis; Heparin Antagonists; Humans; Hypertension, Pul | 1996 |
Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension.
Topics: Female; Hemodynamics; Humans; Hypertension, Pulmonary; Ketanserin; Lung Diseases, Obstructive; Male; | 1997 |
Ketanserin in the treatment of pulmonary hypertension after valvular surgery: comparison with sodium nitroprusside.
Topics: Heart Valve Diseases; Humans; Hypertension, Pulmonary; Ketanserin; Nitroprusside; Postoperative Comp | 1990 |
Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin.
Topics: Blood Platelet Disorders; Blood Platelets; Blood Pressure; Humans; Hypertension, Pulmonary; Ketanser | 1990 |
Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin.
Topics: Animals; Dogs; Hypertension, Pulmonary; Ketanserin; Piperidines; Pulmonary Artery; Pulmonary Embolis | 1985 |
Relationship of increased lung serotonin levels to endotoxin-induced pulmonary hypertension in sheep. Effect of a serotonin antagonist.
Topics: Animals; Blood Pressure; Endotoxins; Escherichia coli; Hypertension, Pulmonary; Hypoxia; Ketanserin; | 1985 |
Comparative effects of oxygen, nifedipine and ketanserin in hypoxic pulmonary hypertension.
Topics: Adult; Carbon Dioxide; Cardiac Output; Female; Heart Rate; Humans; Hypertension, Pulmonary; Hypoxia; | 1985 |
Effects of nitroprusside and ketanserin upon pulmonary edema after acid injury.
Topics: Animals; Capillary Permeability; Dogs; Ferricyanides; Hydrostatic Pressure; Hypertension, Pulmonary; | 1988 |
Effects of serotonin inhibition in air embolism in dogs.
Topics: Animals; Blood Pressure; Dogs; Embolism, Air; Hypertension, Pulmonary; Hypoxia; Ketanserin; Serotoni | 1988 |
Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Cardiac Catheterization; Cardiac Output; Female; Hemodynami | 1987 |
Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Female; Humans; Hypertension, Pulmonary; Ketanserin; Ma | 1987 |